ACA
AQST icon

Adirondack Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Adirondack Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Hold
12,000
– – 0.03% 45
2026
Q1 		$49.8K Buy
+12,000
New +$48.7K 0.03% 43

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Adirondack Capital Advisors's AQST Position: Q2 2026 in Review

Adirondack Capital Advisors held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 12,000 shares worth $49.9K. The position accounts for 0.03% of the portfolio, ranked #45.

Adirondack Capital Advisors first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Adirondack Capital Advisors held 12,000 shares of Aquestive Therapeutics worth $49.9K as of Q2 2026.
  • Adirondack Capital Advisors left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.03% of Adirondack Capital Advisors's portfolio in Q2 2026, its #45 holding.
  • Adirondack Capital Advisors first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Adirondack Capital Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.